2024
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.Peer-Reviewed Original ResearchRelapse-free survivalNewly diagnosed acute myeloid leukemiaOral-AZAIntensive chemotherapyAcute myeloid leukemiaOverall survivalMyeloid leukemiaMedian relapse-free survivalFlatiron Health databasePropensity score matched cohortCompare treatment patternsScore-matched cohortAzacitidine maintenanceND-AMLOral azacitidineMedian OSRetrospective studyClinical outcomesTreatment patternsAzacitidineTransplant candidatesPatientsReal-world outcomesRemissionChemotherapyHealthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study
Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study. Advances In Therapy 2024, 41: 4049-4064. PMID: 39240504, PMCID: PMC11480148, DOI: 10.1007/s12325-024-02947-1.Peer-Reviewed Original ResearchAcute myeloid leukemiaHealthcare resource utilizationOral-AZAPropensity score matchingMyeloid leukemiaReal-world healthcare resource utilizationClinical practiceHematopoietic stem cell transplantationLower healthcare resource utilizationResultsAfter propensity score matchingStem cell transplantationContinuous insurance enrollmentClaims database studyOutpatient visitsOral azacitidinePost-remissionMaintenance therapyProlonged remissionCell transplantationDisease remissionDelayed relapseBaseline characteristicsTreatment patternsPatientsDatabase studyA post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.
Voso M, De Botton S, Pfeilstöcker M, Figuera Alvarez A, Wang K, L. See W, Ugidos Guerrero M, Lopes de Menezes D, Petrlik E, Prebet T, Roboz G. A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study. Journal Of Clinical Oncology 2024, 42: 6522-6522. DOI: 10.1200/jco.2024.42.16_suppl.6522.Peer-Reviewed Original ResearchRelapse-free survivalHematopoietic stem cell transplantationOral-AZAPoor-risk cytogeneticsAML-MRCOutcomes of patientsMedian OSOverall survivalTreatment armsMedian relapse-free survivalAnalysis of outcomes of patientsProlonged median OSMyelodysplasia-related changesStem cell transplantationPhase 3 studyKaplan-Meier methodAcute myeloid leukemiaEffective treatment optionYears of agePost hoc analysisOral azacitidinePlacebo QDImproved OSMRD negativitySecondary AMLPreliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.
Garcia-Manero G, Yee K, Hernandez F, Della Porta M, Paolini S, Ahn S, Santini V, Fenaux P, Suzuki T, Sekeres M, He J, Li J, Barkalifa R, Vigil C, Prebet T, Lopes de Menezes D, Burnett J, Komrokji R, Giagounidis A. Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial. Journal Of Clinical Oncology 2024, 42: 6509-6509. DOI: 10.1200/jco.2024.42.16_suppl.6509.Peer-Reviewed Original ResearchLower-risk MDSOral-AZAMyelodysplastic syndromeAdverse eventsPreliminary efficacy dataComplete remissionEfficacy dataOverall responseLower-risk myelodysplastic syndromesHigher-risk myelodysplastic syndromesIPSS-R scoreRBC transfusion burdenRate of adverse eventsDose-optimization studyErythropoiesis-stimulating agentsSerious adverse eventsAcute myeloid leukemiaMITT populationOral azacitidineTransfusion burdenIPSS-ROpen-labelEligible ptsPhase 2/3Primary endpointCorrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]
Mims A, Xie Z, Vasconcelos A, Strocchia M, Heydendael W, Chevli M, Rotter D, Potluri R, Prebet T, Sieluk J. Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 203-204. DOI: 10.1016/j.clml.2023.11.010.Peer-Reviewed Original Research
2023
EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database
Borate U, Seiter K, Potluri R, Mazumder D, Heydendael W, Chevli M, Prebet T, Strocchia M, Vasconcelos A, Sieluk J. EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database. Value In Health 2023, 26: s67. DOI: 10.1016/j.jval.2023.09.358.Peer-Reviewed Original Research